Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
2.955
-0.105 (-3.43%)
Apr 23, 2026, 12:43 PM EDT - Market open
Cyclerion Therapeutics Revenue
In the year 2025, Cyclerion Therapeutics had annual revenue of $2.07M with 3.70% growth. Cyclerion Therapeutics had revenue of $1.03M in the quarter ending December 31, 2025, a decrease of -43.24%.
Revenue (ttm)
$2.07M
Revenue Growth
+3.70%
P/S Ratio
6.24
Revenue / Employee
$2,074,000
Employees
1
Market Cap
12.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.07M | 74.00K | 3.70% |
| Dec 31, 2024 | 2.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 297.00K | -3.65M | -92.47% |
| Dec 31, 2021 | 3.94M | 1.65M | 71.69% |
| Dec 31, 2020 | 2.30M | -2.21M | -49.06% |
| Dec 31, 2019 | 4.51M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCYCN News
- 22 days ago - Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing - Benzinga
- 22 days ago - Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
- 2 months ago - Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board - GlobeNewsWire
- 3 months ago - Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewsWire
- 7 months ago - Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company - GlobeNewsWire
- 1 year ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 1 year ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 2 years ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire